Helix BioPharma Corp.
TSX:HBP.TO
0.9 (CAD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Helix BioPharma Corp. |
Symbool | HBP.TO |
Munteenheid | CAD |
Prijs | 0.9 |
Beurswaarde | 44,119,350 |
Dividendpercentage | 0% |
52-weken bereik | 0.8 - 1.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jacek Antas |
Website | https://www.helixbiopharma.com |
An error occurred while fetching data.
Over Helix BioPharma Corp.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CAD)
Cijfers zijn in miljoenen (CAD)